Recent advances and future perspectives of noncompetitive proteasome inhibitors.

[1]  M. Groettrup,et al.  Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome , 2022, European journal of immunology.

[2]  K. Świderek,et al.  Covalent Inhibition of the Human 20S Proteasome with Homobelactosin C Inquired by QM/MM Studies , 2022, Pharmaceuticals.

[3]  R. Guedes,et al.  Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance , 2022, Molecules.

[4]  Abida,et al.  Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021 , 2022, Expert opinion on therapeutic patents.

[5]  E. Cencini,et al.  Drug resistance and minimal residual disease in multiple myeloma , 2022, Cancer drug resistance.

[6]  R. A. Fan,et al.  Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism , 2021, International journal of molecular sciences.

[7]  Álvaro Cortés Cabrera,et al.  High Throughput Screening to Identify Selective and Nonpeptidomimetic Proteasome Inhibitors As Antimalarials. , 2021, ACS infectious diseases.

[8]  Heba A. Hassan,et al.  JNK signaling as a target for anticancer therapy , 2021, Pharmacological Reports.

[9]  P. Cascio.  PA28γ: New Insights on an Ancient Proteasome Activator , 2021, Biomolecules.

[10]  Andreas Martin,et al.  Proteasome interaction with ubiquitinated substrates: from mechanisms to therapies , 2020, The FEBS journal.

[11]  G. Martinelli,et al.  Old and new generation proteasome inhibitors in multiple myeloma. , 2020, Panminerva medica.

[12]  F. Supek,et al.  Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases , 2020, Journal of medicinal chemistry.

[13]  V. Uversky,et al.  Unstructured Biology of Proteins from Ubiquitin-Proteasome System: Roles in Cancer and Neurodegenerative Diseases , 2020, Biomolecules.

[14]  T. Meul,et al.  Exploring the proteasome system: A novel concept of proteasome inhibition and regulation. , 2020, Pharmacology & therapeutics.

[15]  C. Aldrich,et al.  Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome , 2020, Molecules.

[16]  S. Grossman,et al.  Harnessing the vulnerabilities of p53 mutants in lung cancer – Focusing on the proteasome: a new trick for an old foe? , 2020, Cancer biology & therapy.

[17]  Marianne E. Maresh,et al.  The Immunoproteasome: An Emerging Target in Cancer, Autoimmune and Neurological Disorders. , 2020, Journal of medicinal chemistry.

[18]  Jiankang Zhang,et al.  Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. , 2019, European journal of medicinal chemistry.

[19]  F. Gamo,et al.  Identification of small molecules disrupting the ubiquitin proteasome system in malaria. , 2019, ACS infectious diseases.

[20]  David M. Smith,et al.  A Practical Review of Proteasome Pharmacology , 2019, Pharmacological Reviews.

[21]  J. Tepe,et al.  Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders. , 2019, Journal of medicinal chemistry.

[22]  P. Osmulski,et al.  Pipecolic esters as minimized templates for proteasome inhibition. , 2019, Organic & biomolecular chemistry.

[23]  T. Muchamuel,et al.  Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide). , 2018, Journal of medicinal chemistry.

[24]  Andreas Martin,et al.  Structure and Function of the 26S Proteasome. , 2018, Annual review of biochemistry.

[25]  M. Petrucci,et al.  Proteasome inhibitors for the treatment of multiple myeloma , 2018, Expert opinion on pharmacotherapy.

[26]  A. Allegra,et al.  Immunoproteasome‐selective and non‐selective inhibitors: A promising approach for the treatment of multiple myeloma , 2017, Pharmacology & therapeutics.

[27]  Shagufta,et al.  Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. , 2018, European journal of medicinal chemistry.

[28]  J. Laubach,et al.  The proteasome and proteasome inhibitors in multiple myeloma , 2017, Cancer and Metastasis Reviews.

[29]  Huilin Li,et al.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes , 2017, Nature Communications.

[30]  M. Hochstrasser,et al.  Proteasome Structure and Assembly. , 2017, Journal of molecular biology.

[31]  Q. Dou,et al.  Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing , 2017, Cancer and Metastasis Reviews.

[32]  M. J. Chen,et al.  Reversible phosphorylation of the 26S proteasome , 2017, Protein & Cell.

[33]  Glen Spraggon,et al.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.

[34]  M. Chance,et al.  Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine. , 2016, Sultan Qaboos University medical journal.

[35]  M. Groettrup,et al.  The immunoproteasome: a novel drug target for autoimmune diseases. , 2015, Clinical and experimental rheumatology.

[36]  J. Sacchettini,et al.  Crystal structure of the human 20S proteasome in complex with carfilzomib. , 2015, Structure.

[37]  P. Osmulski,et al.  Harnessing proteasome dynamics and allostery in drug design. , 2014, Antioxidants & redox signaling.

[38]  E. Hol,et al.  The ubiquitin proteasome system in glia and its role in neurodegenerative diseases , 2014, Front. Mol. Neurosci..

[39]  E. Jankowska,et al.  Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome , 2014, Journal of peptide science : an official publication of the European Peptide Society.

[40]  S. Ševčíková,et al.  Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma , 2014, Journal of cellular and molecular medicine.

[41]  T. Kunoh,et al.  A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor. , 2014, European journal of medicinal chemistry.

[42]  Marion Schmidt,et al.  Regulation of proteasome activity in health and disease. , 2014, Biochimica et biophysica acta.

[43]  M. Groettrup,et al.  The unique functions of tissue-specific proteasomes. , 2014, Trends in biochemical sciences.

[44]  Jacob R. Ludwig,et al.  Inhibition of the human proteasome by imidazoline scaffolds. , 2013, Journal of medicinal chemistry.

[45]  P. Osmulski,et al.  Rapamycin Allosterically Inhibits the Proteasome , 2013, Molecular Pharmacology.

[46]  A. Ciechanover.  Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. , 2013, Bioorganic & medicinal chemistry.

[47]  N. Munshi,et al.  In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells , 2013, Clinical Cancer Research.

[48]  R. W. Henry,et al.  Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo. , 2013, ACS chemical biology.

[49]  M. Groettrup,et al.  The immunoproteasome in antigen processing and other immunological functions. , 2013, Current opinion in immunology.

[50]  Durga Prasad Mishra,et al.  Therapeutic targeting of cancer cell cycle using proteasome inhibitors , 2012, Cell Division.

[51]  Lewis E. Kay,et al.  Proteasome allostery as a population shift between interchanging conformers , 2012, Proceedings of the National Academy of Sciences.

[52]  M. Groll,et al.  Covalent and non-covalent reversible proteasome inhibition , 2012, Biological chemistry.

[53]  K. Anderson,et al.  Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies. , 2012, Seminars in hematology.

[54]  M. Rapé,et al.  The Ubiquitin Code , 2012, Annual review of biochemistry.

[55]  G. Nalini,et al.  The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases , 2012, International journal of rheumatic diseases.

[56]  Ricarda Schwab,et al.  Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity , 2012, Cell.

[57]  S. Bhaumik,et al.  The 26S proteasome complex: an attractive target for cancer therapy. , 2012, Biochimica et biophysica acta.

[58]  D. Ferrington,et al.  Immunoproteasomes: structure, function, and antigen presentation. , 2012, Progress in molecular biology and translational science.

[59]  P. Walter,et al.  The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation , 2011, Science.

[60]  Dominique N. Soroka,et al.  Synthesis and proteasome inhibition of lithocholic acid derivatives. , 2011, Bioorganic & medicinal chemistry letters.

[61]  T. Muchamuel,et al.  Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events , 2011, Clinical Cancer Research.

[62]  L. Crawford,et al.  Proteasome inhibitors in cancer therapy , 2011, Journal of Cell Communication and Signaling.

[63]  Axel A. Brakhage,et al.  Biosynthesis and function of gliotoxin in Aspergillus fumigatus , 2011, Applied Microbiology and Biotechnology.

[64]  Youming Xie.  Structure, assembly and homeostatic regulation of the 26S proteasome. , 2010, Journal of molecular cell biology.

[65]  L. Kay,et al.  Effect of noncompetitive proteasome inhibition on bortezomib resistance. , 2010, Journal of the National Cancer Institute.

[66]  E. Jankowska,et al.  Potential allosteric modulators of the proteasome activity. , 2010, Biopolymers.

[67]  K. Sadre-Bazzaz,et al.  Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening. , 2010, Molecular cell.

[68]  John R. Barrett,et al.  Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen–sensitive and resistant ER+ breast cancer cells , 2010, Autophagy.

[69]  M. Wenner.  A new kind of drug target. , 2009, Scientific American.

[70]  J. Thornton,et al.  The structural basis of allosteric regulation in proteins , 2009, FEBS letters.

[71]  A. H. Drummond,et al.  Aminopeptidase inhibition as a targeted treatment strategy in myeloma , 2009, Molecular Cancer Therapeutics.

[72]  Keiji Tanaka,et al.  Molecular mechanisms of proteasome assembly , 2009, Nature Reviews Molecular Cell Biology.

[73]  D. Groebe.  In search of negative allosteric modulators of biological targets. , 2009, Drug discovery today.

[74]  M. Simons,et al.  Molecular basis for proline- and arginine-rich peptide inhibition of proteasome. , 2008, Journal of molecular biology.

[75]  B. Mordmüller,et al.  Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon , 2008, Malaria Journal.

[76]  M. Herlyn,et al.  Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway , 2008, Molecular Cancer Therapeutics.

[77]  L. Kay,et al.  TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. , 2008, Biochemistry.

[78]  Keiji Tanaka,et al.  Regulation of CD8+ T Cell Development by Thymus-Specific Proteasomes , 2007, Science.

[79]  T. Wandless,et al.  The Rapamycin-binding Domain of the Protein Kinase Mammalian Target of Rapamycin Is a Destabilizing Domain* , 2007, Journal of Biological Chemistry.

[80]  A. Goldberg.  Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. , 2007, Biochemical Society transactions.

[81]  Huilin Li,et al.  Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate , 2006, Molecular microbiology.

[82]  Xuyang Peng,et al.  The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. , 2005, Molecular interventions.

[83]  E. Strickland,et al.  Recognition and processing of misfolded proteins by PA700, the 19S regulatory complex of the 26S proteasome. , 2005, Methods in molecular biology.

[84]  P. Osmulski,et al.  Characterization of noncompetitive regulators of proteasome activity. , 2005, Methods in enzymology.

[85]  S. Fang,et al.  Ubiquitin-proteasome system , 2004, Cellular and Molecular Life Sciences CMLS.

[86]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[87]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[88]  Robert E. Cohen,et al.  Proteasomes and their kin: proteases in the machine age , 2004, Nature Reviews Molecular Cell Biology.

[89]  P. Osmulski,et al.  Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. , 2003, Biochemistry.

[90]  J. Adams,et al.  The proteasome: structure, function, and role in the cell. , 2003, Cancer treatment reviews.

[91]  J. Adams.  Potential for proteasome inhibition in the treatment of cancer. , 2003, Drug discovery today.

[92]  J. Satoh,et al.  Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome. , 2002, International journal of oncology.

[93]  H. Nakagawa,et al.  The role of the proteasome in apoptosis induced by anthracycline anticancer agents. , 2002, International journal of oncology.

[94]  M. Roisin,et al.  In vitro effects of gliotoxin, a natural proteasome inhibitor, on the infectivity and proteolytic activity of Toxoplasma gondii , 2002, Parasitology Research.

[95]  M. Benincasa,et al.  Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action. , 2002, Current pharmaceutical design.

[96]  W. Aird,et al.  PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBα degradation , 2001 .

[97]  P. Kloetzel,et al.  20S proteasome biogenesis. , 2001, Biochimie.

[98]  A. Goldberg,et al.  Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.

[99]  A. Goldberg,et al.  Inhibition of ubiquitin-proteasome pathway–mediated IκBα degradation by a naturally occurring antibacterial peptide , 2000 .

[100]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[101]  B. DeDecker,et al.  Allosteric drugs: thinking outside the active-site box. , 2000, Chemistry & biology.

[102]  A. Ciechanover,et al.  Ubiquitin‐mediated proteolysis: biological regulation via destruction , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[103]  D. Thomas,et al.  The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. , 1999, Chemistry & biology.

[104]  D. Wolf,et al.  The Active Sites of the Eukaryotic 20 S Proteasome and Their Involvement in Subunit Precursor Processing* , 1997, The Journal of Biological Chemistry.

[105]  Wei Chen,et al.  The Antitumor Drug Aclacinomycin A, Which Inhibits the Degradation of Ubiquitinated Proteins, Shows Selectivity for the Chymotrypsin-like Activity of the Bovine Pituitary 20 S Proteasome* , 1996, The Journal of Biological Chemistry.

[106]  P. Bayer,et al.  Structural studies of HIV-1 Tat protein. , 1995, Journal of molecular biology.

[107]  A. Ciechanover,et al.  The 26S proteasome of the yeast Saccharomyces cerevisiae , 1994, FEBS letters.

[108]  Keiji Tanaka.  Role of proteasomes modified by interferon‐γ in antigen processing , 1994, Journal of leukocyte biology.

[109]  A. Goldberg,et al.  A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. , 1977, Proceedings of the National Academy of Sciences of the United States of America.